Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Pharmacotherapy
|
February 12, 2002
Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections
Jim Zhiming Li, Richard J Willke, Brian E Rittenhouse, et al.
American Journal of Lifestyle Medicine
|
January 24, 2025
Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study
Sultan Alolayan, Tewodros Eguale, Alissa R Segal, et al.
Diabetes, Obesity & Metabolism
|
August 14, 2024
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was
Brian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
International Journal of Technology Assessment in Health Care
|
October 24, 2002
Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis
Richard J Willke, Henry A Glick, Jim Z Li, et al.
Surgical Infections
|
May 15, 2003
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial
Jim Zhiming Li, Richard J Willke, Brian E Rittenhouse, et al.
Preventive Medicine
|
December 13, 2023
The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply
Brian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
American Journal of Therapeutics
|
July 8, 2003
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals
Angela G Vinken, Jim Z Li, Dan A Balan, et al.
International Journal of Antimicrobial Agents
|
April 15, 2004
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects
Dilip Nathwani, Jim Z Li, Dan A Balan, et al.
Clinical Therapeutics
|
July 16, 2003
Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial
Horacio López, Jim Z Li, Dan A Balan, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Pharmacotherapy
|
February 12, 2002
Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections
Jim Zhiming Li, Richard J Willke, Brian E Rittenhouse, et al.
American Journal of Lifestyle Medicine
|
January 24, 2025
Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study
Sultan Alolayan, Tewodros Eguale, Alissa R Segal, et al.
Diabetes, Obesity & Metabolism
|
August 14, 2024
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was
Brian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
International Journal of Technology Assessment in Health Care
|
October 24, 2002
Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis
Richard J Willke, Henry A Glick, Jim Z Li, et al.
Surgical Infections
|
May 15, 2003
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial
Jim Zhiming Li, Richard J Willke, Brian E Rittenhouse, et al.
Preventive Medicine
|
December 13, 2023
The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply
Brian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
American Journal of Therapeutics
|
July 8, 2003
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals
Angela G Vinken, Jim Z Li, Dan A Balan, et al.
International Journal of Antimicrobial Agents
|
April 15, 2004
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects
Dilip Nathwani, Jim Z Li, Dan A Balan, et al.
Clinical Therapeutics
|
July 16, 2003
Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial
Horacio López, Jim Z Li, Dan A Balan, et al.
Page
of 1